Matt D'Auria

Sales & Marketing

Matt D’Auria is a talent-centric leader who has been building and leading medical communications teams for over 20 years.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.